Pharvaris Announces Annual Meeting of Shareholders

Company Overview - Pharvaris is a late-stage biopharmaceutical company focused on developing novel, oral bradykinin B2 receptor antagonists aimed at treating and preventing hereditary angioedema (HAE) attacks [4] - The company aims to provide efficacious, safe, and easy-to-administer treatment alternatives for all sub-types of HAE, both on-demand and prophylactically [4] Upcoming Events - The annual general meeting of shareholders is scheduled for June 28, 2024, at 15:00 CEST (9:00 a.m. EDT) [1] - Relevant documents and information regarding the annual general meeting will be available in the "Investors" section of Pharvaris' website and on the SEC's website [3]